Clinical efficacy of Mesalazine in patients with diarrhea-dominant irritable bowel syndrome with elevated fecal calprotectin referred to Emam Reza Hospital of Tabriz: a randomized double-blind, placebo-controlled trial

Abstract

Irritable bowel syndrome (IBS) is the most common disorder of gastrointestinal system that affects about 14-22% of the population. The aim of this study was to determine the effect of mesalazine prescription on patients' symptoms and level of fecal calprotectin in patients with IBS with predominant diarrhea and high fecal calprotectin. Materials and Methods: The present study is a double-blind randomized clinical trial in patients with IBS referred to gastrointestinal disease clinics affiliated to Tabriz University of Medical Sciences, in which diagnosis was made according to Rome IV criteria by a physician. The predominant symptoms of patients were diarrhea with high fecal calprotectin levels and normal colonoscopy. Results: In comparison between before and after mesalazine therapy in our patients marked a statistically significant effect on quality of life (QOL) variables, patient’s level of pain, abdominal distension and calprotectin compared to before mesalazine in patients studied, which showed the effectiveness of this treatment. In these patients show.